8225.HK
China Health Group Inc. [8225.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
8225.HK Stock Summary
In the News
8225.HK Financial details
Company Rating
Neutral
Market Cap
108.49M
Income
-26.26M
Revenue
-2.33M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-5.42
Forward P/E
-
PEG
0.32
P/S
-61.02
P/B
0.96
P/C
-
P/FCF
-
Quick Ratio
0.19
Current Ratio
4.39
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.03
EPS next Y
-
EPS next Q
-
EPS this Y
-143.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-26.15%
Revenue Q/Q
-73.97%
EPS Q/Q
-98.04%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-14%
ROE
-18%
ROC
-0.19%
Gross Margin
313%
Oper. Margin
1206%
Profit Margin
1126%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.103-0.248
52W High
-
52W Low
-
RSI
22
Rel Volume
8.34
Avg Volume
38.39K
Volume
320K
Perf Week
-19.26%
Perf Month
-26.35%
Perf Quarter
-
Perf Half Y
-34.73%
-
-
-
-
Beta
-2.313
-
-
Volatility
0.01%, 0.01%
Prev Close
11.22%
Price
0.109
Change
21.11%
8225.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.06 | 0.06 | 0.08 | 0.08 | 0.01 | |
| Net income per share | 0.02 | 0.03 | 0.06 | 0.04 | -0.02 | |
| Operating cash flow per share | 0 | 0 | 0.02 | -0.01 | -0.01 | |
| Free cash flow per share | 0 | 0 | 0.02 | -0.01 | -0.01 | |
| Cash per share | 0.01 | 0.01 | 0.03 | 0.02 | 0.01 | |
| Book value per share | 0.03 | 0.06 | 0.12 | 0.16 | 0.14 | |
| Tangible book value per share | 0.03 | 0.06 | 0.12 | 0.16 | 0.14 | |
| Share holders equity per share | 0.03 | 0.06 | 0.12 | 0.16 | 0.14 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 156.81M | 91.3M | 342.96M | 312.76M | 254.91M | |
| Enterprise value | 149.3M | 86.96M | 328.27M | 301.39M | 250.85M | |
| P/E ratio | 6.77 | 3.29 | 5.65 | 8.61 | -16.09 | |
| Price to sales ratio | 2.63 | 1.44 | 4.13 | 3.74 | 19.47 | |
| POCF ratio | 54.87 | -188.26 | 17.94 | -30.43 | -49.44 | |
| PFCF ratio | 124.06 | -187.87 | 17.94 | -30.43 | -49.44 | |
| P/B Ratio | 5.37 | 1.6 | 2.89 | 2.01 | 1.79 | |
| PTB ratio | 5.37 | 1.6 | 2.89 | 2.01 | 1.79 | |
| EV to sales | 2.5 | 1.38 | 3.95 | 3.61 | 19.16 | |
| Enterprise value over EBITDA | 5.19 | 2.57 | 5.9 | 7.06 | -16.02 | |
| EV to operating cash flow | 52.24 | -179.31 | 17.17 | -29.33 | -48.65 | |
| EV to free cash flow | 118.12 | -178.94 | 17.17 | -29.33 | -48.65 | |
| Earnings yield | 0.15 | 0.3 | 0.18 | 0.12 | -0.06 | |
| Free cash flow yield | 0.01 | -0.01 | 0.06 | -0.03 | -0.02 | |
| Debt to equity | 0.05 | 0.07 | 0.01 | 0 | 0 | |
| Debt to assets | 0.02 | 0.04 | 0.01 | 0 | 0 | |
| Net debt to EBITDA | -0.26 | -0.13 | -0.26 | -0.27 | 0.26 | |
| Current ratio | 1.65 | 2.06 | 3.84 | 4.62 | 4.82 | |
| Interest coverage | 440.17 | 189.69 | 339.72 | 2.83K | -929.94 | |
| Income quality | 0.1 | -0.01 | 0.27 | -0.24 | 0.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.14 | 0.1 | 0.04 | 0.17 | 1.07 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.56 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.03 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.53 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.01 | 0.16 | |
| Graham number | 0.12 | 0.19 | 0.4 | 0.36 | 0.23 | |
| ROIC | 0.76 | 0.44 | 0.39 | 0.23 | -0.11 | |
| Return on tangible assets | 0.34 | 0.25 | 0.38 | 0.18 | -0.09 | |
| Graham Net | -0.03 | 0 | 0.05 | 0.07 | 0.05 | |
| Working capital | 25.89M | 54.74M | 116.92M | 154.02M | 140.48M | |
| Tangible asset value | 29.19M | 56.98M | 118.68M | 155.57M | 141.88M | |
| Net current asset value | 25.89M | 52.21M | 116.92M | 154.02M | 140.48M | |
| Invested capital | 0.05 | 0.07 | 0.01 | 0 | 0 | |
| Average receivables | 0 | 29.28M | 72.31M | 107.28M | 118.67M | |
| Average payables | 664.5K | 4.07M | 7.77M | 9.78M | 8.33M | |
| Average inventory | 1.21M | 0 | -6.08M | -8.91M | -6.83M | |
| Days sales outstanding | 0 | 338.1 | 378.15 | 561.08 | 3.03K | |
| Days payables outstanding | 64.83 | 256.19 | 196.89 | 201.13 | 287.35 | |
| Days of inventory on hand | 0 | 0 | -275.61 | -104.63 | -397.94 | |
| Receivables turnover | 0 | 1.08 | 0.97 | 0.65 | 0.12 | |
| Payables turnover | 5.63 | 1.42 | 1.85 | 1.81 | 1.27 | |
| Inventory turnover | 0 | 0 | -1.32 | -3.49 | -0.92 | |
| ROE | 0.79 | 0.49 | 0.51 | 0.23 | -0.11 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | -0.02 | 0 | 0.01 | 0 | |
| Net income per share | 0 | -0.03 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Book value per share | 0.17 | 0.14 | 0.14 | 0.15 | 0 | |
| Tangible book value per share | 0 | 0.14 | 0 | 0.15 | 0 | |
| Share holders equity per share | 0.17 | 0.14 | 0.14 | 0.15 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 275.15M | 254.91M | 215.81M | 170.17M | 136.34M | |
| Enterprise value | 287.89M | 250.85M | 227.88M | 165.63M | 0 | |
| P/E ratio | 568.49 | -1.98 | 60.55 | 8.62 | 315.6 | |
| Price to sales ratio | 91.2 | -12.6 | 53.94 | 15.44 | 47.52 | |
| POCF ratio | 0 | 119.28 | 0 | 129.26 | 0 | |
| PFCF ratio | 0 | 119.28 | 0 | 129.26 | 0 | |
| P/B Ratio | 1.6 | 1.79 | 1.52 | 1.15 | 0 | |
| PTB ratio | 1.6 | 1.79 | 1.52 | 1.15 | 0 | |
| EV to sales | 95.42 | -12.4 | 56.95 | 15.02 | 0 | |
| Enterprise value over EBITDA | 1.59K | -7.15 | 224.73 | 28.59 | 0 | |
| EV to operating cash flow | 0 | 117.38 | 0 | 125.82 | 0 | |
| EV to free cash flow | 0 | 117.38 | 0 | 125.82 | 0 | |
| Earnings yield | 0 | -0.13 | 0 | 0.03 | 0 | |
| Free cash flow yield | 0 | 0.01 | 0 | 0.01 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 70.42 | 0.12 | 11.9 | -0.78 | 0 | |
| Current ratio | 0 | 4.82 | 0 | 4.39 | 0 | |
| Interest coverage | 4.64 | 2.51K | 263 | 0 | 16.88 | |
| Income quality | 0 | -0.07 | 0 | 0.27 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.47 | -0.44 | 0.49 | -0.08 | 0.48 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | -0.11 | 0 | 0 | 0 | |
| Graham number | 0.02 | 0.32 | 0.05 | 0.13 | 0 | |
| ROIC | 0 | -0.23 | 0.01 | 0.03 | 0 | |
| Return on tangible assets | 0 | -0.18 | 0 | 0.03 | 0 | |
| Graham Net | 0.01 | 0.05 | 0.01 | 0.05 | 0 | |
| Working capital | 12.75M | 140.48M | 12.07M | 145.55M | 0 | |
| Tangible asset value | 0 | 141.88M | 0 | 147.79M | 0 | |
| Net current asset value | 12.75M | 140.48M | 12.07M | 145.63M | 0 | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 71.38M | 54.41M | 54.41M | 58.87M | 0 | |
| Average payables | 10.06M | 2.89M | 2.89M | 10.27M | 0 | |
| Average inventory | -2.83M | -4.01M | -4.01M | -1.8M | 0 | |
| Days sales outstanding | 0 | -484.24 | 0 | 961.3 | 0 | |
| Days payables outstanding | 0 | -295.77 | 0 | 428.39 | 0 | |
| Days of inventory on hand | 0 | 409.6 | 0 | -75.13 | 0 | |
| Receivables turnover | 0 | -0.19 | 0 | 0.09 | 0 | |
| Payables turnover | 0 | -0.3 | 0 | 0.21 | 0 | |
| Inventory turnover | 0 | 0.22 | 0 | -1.2 | 0 | |
| ROE | 0 | -0.23 | 0.01 | 0.03 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
8225.HK Frequently Asked Questions
What is China Health Group Inc. stock symbol ?
China Health Group Inc. is a CN stock and trading under the symbol 8225.HK
What is China Health Group Inc. stock quote today ?
China Health Group Inc. stock price is $0.109 today.
Is China Health Group Inc. stock public?
Yes, China Health Group Inc. is a publicly traded company.
Company Profile
- Volume Average 38.39K
- Market Capitalization 108.49M
- Employee 42
- CEO Dr. Xuemei Song
- Headquarters Beijing,CN
- IPO Date 2003-07-10
-
Website
https://www.chgi.net 
China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People's Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drug technologies. The company was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. China Health Group Inc. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
